Tempest Therapeutics (TPST) Corporate presentation summary

Platform and therapeutic strategy

• Immune reset strategy aims to clear diseased immune cells and restore healthy immunity across cancer and autoimmune diseases.

• TPST-4903 uses CD7-targeted lentiviral delivery with a BCMA × GPRC5D payload for relapsed/refractory multiple myeloma; TPST-4003 uses CD7-targeted LNP delivery with a CD19 × BCMA payload.

• The development thesis pairs targeted LNP delivery for autoimmune disease with targeted LVV delivery for cancer, using CD7-targeted delivery and dual-target CAR payloads.

Clinical pipeline and early evidence

• TPST-4903 is in Phase 1; six relapsed/refractory multiple myeloma patients were treated, with no grade ≥3 CRS or ICANS observed.

• CAR-T cell expansion was observed at two weeks post infusion; the initial safety profile supports continued dose escalation, with a clinical update expected Q4 2026.

• TPST-4003 Phase 1 enrollment in MG, MS and SLE is planned for Q4 2026.

• Autologous dual-target CAR-T results cited as support included CR in 10/10 relapsed/refractory multiple myeloma CAR-T-naïve patients and median PFS of 23.1 months; cross-trial comparisons are not head-to-head.

Market opportunity

• Addressable settings span LBCL, B-ALL, relapsed/refractory multiple myeloma and extramedullary disease, plus MG, MS, SLE and POEMS.

• The cited 7MM DLBCL market is projected to grow from $5.3B in 2025 to $16.6B in 2034; the CAR-T multiple myeloma market from $3.1B in 2024 to $15.4B in 2034.

• Cited global markets include MS drugs at $22.3B in 2025, projected to $39.7B in 2036, and SLE at $2.60B in 2023, projected to $4.26B in 2030.

• Strategic rationale includes unmet need in extramedullary multiple myeloma and refractory autoimmune populations, and potential broader access through scalable formats.